People Background Check
Find People:

Benjamin M Segal, Age 62315 2Nd St APT 214, Ann Arbor, MI 48103

Get Report
Known as:
Benjamin L Segal
Related to:
Tracy Renee Segal 53 Martin C Segal 79

Benjamin Segal Phones & Addresses

315 2Nd St APT 214, Ann Arbor, MI 48103 (734) 730-9390

Columbus, OH

177 Grosvenor Rd, Rochester, NY 14610

Penn Yan, NY

Bethesda, MD

Scottsdale, AZ

Work

Company: U OF M TAUBMAN CENTER MEDICAL CLINIC Address: 1500 E Medical Center Dr Suite 5322, Ann Arbor, MI 48109 Phones: (734) 936-9010 (Phone) (734) 615-4991 (Fax)

Education

School / High School: Brown University / Alpert Medical School 1988

Languages

English

Awards

Healthgrades Honor Roll

Ranks

Certificate: Neurology, 1994

Mentions for Benjamin M Segal

Career records & work history

Medicine Doctors

Benjamin Segal Photo 1

Dr. Benjamin M Segal, Ann Arbor MI - MD (Doctor of Medicine)

Specialties:
Neuropsychiatry (Neurology)
Address:
U OF M TAUBMAN CENTER MEDICAL CLINIC
1500 E Medical Center Dr Suite 5322, Ann Arbor, MI 48109
(734) 936-9010 (Phone) (734) 615-4991 (Fax)
Certifications:
Neurology, 1994
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
U OF M TAUBMAN CENTER MEDICAL CLINIC
1500 E Medical Center Dr Suite 5322, Ann Arbor, MI 48109
University of Michigan Health System
1500 East Medical Center Drive Spc 5474, Ann Arbor, MI 48109
Education:
Medical School
Brown University / Alpert Medical School
Graduated: 1988

Benjamin Segal

Specialties:
Neurology
Work:
University Of Michigan Neurology
1500 E Medical Ctr Dr FL 1-C, Ann Arbor, MI 48109
(734) 936-9020 (phone) (734) 936-4991 (fax)
Languages:
English
Description:
Dr. Segal works in Ann Arbor, MI and specializes in Neurology. Dr. Segal is affiliated with VA Ann Arbor Healthcare System.

Benjamin Segal resumes & CV records

Resumes

Benjamin Segal Photo 30

Professor

Location:
Ann Arbor, MI
Industry:
Higher Education
Work:
University of Michigan
Professor
Education:
Brown University 1980 - 1984
Bachelors
Benjamin Segal Photo 31

Professor

Location:
Ann Arbor, MI
Work:
University of Michigan Medical School
Professor
Benjamin Segal Photo 32

Benjamin Segal

Publications & IP owners

Us Patents

Lymphoid Chemokines In The Diagnosis, Monitoring And Treatment Of Inflammatory Disease

US Patent:
8546538, Oct 1, 2013
Filed:
Apr 9, 2008
Appl. No.:
12/100196
Inventors:
Benjamin M. Segal - Ann Arbor MI, US
Ludmila Bagaeva - Fairport NY, US
Assignee:
University of Rochester - Rochester NY
International Classification:
C07K 16/00
A61K 39/395
US Classification:
5303871, 4241301
Abstract:
Experimental autoimmune encephalomyelitis (EAE) is a Th1-mediated autoimmune disease of the central nervous system that is widely used as an animal model of multiple sclerosis (MS). In this study it was demonstrate that CXCL13, a chemokine involved in the development of secondary lymphoid tissues, is expressed in CD11c+ myeloid cells that accumulate in EAE lesions. Blockade or deficiency of CXCL13 ameliorates clinical EAE, both during acute and relapsing stages. CXCL13 deficiency did not inhibit the priming or differentiation of autoimmune effector T-cells in the periphery, but appeared to exert its effects during the effector phase of pathogenesis. These findings indicate that reagents that antagonize or inhibit CXCL13 are useful for the treatment of neuroinflammatory diseases such as MS.

Lymphoid Chemokines In The Diagnosis, Monitoring And Treatment Of Inflammatory Disease

US Patent:
2006028, Dec 21, 2006
Filed:
Apr 29, 2005
Appl. No.:
11/119333
Inventors:
Benjamin Segal - Rochester NY, US
Ludmila Bagaeva - Fairport NY, US
International Classification:
C12Q 1/68
A61K 39/12
US Classification:
435006000, 424204100
Abstract:
Experimental autoimmune encephalomyelitis (EAE) is a Th1-mediated autoimmune disease of the central nervous system that is widely used as an animal model of multiple sclerosis (MS). In this study it was demonstrate that CXCL13, a chemokine involved in the development of secondary lymphoid tissues, is expressed in CD11c+ myeloid cells that accumulate in EAE lesions. Blockade or deficiency of CXCL13 ameliorates clinical EAE, both during acute and relapsing stages. CXCL13 deficiency did not inhibit the priming or differentiation of autoimmune effector T-cells in the periphery, but appeared to exert its effects during the effector phase of pathogenesis. These findings indicate that reagents that antagonize or inhibit CXCL13 are useful for the treatment of neuroinflammatory diseases such as MS.

Blockade Of Elr+Cxc Chemokines As A Treatment For Inflammatory And Autoimmune Disease

US Patent:
2008020, Aug 28, 2008
Filed:
Jan 4, 2006
Appl. No.:
11/813318
Inventors:
Benjamin Segal - Rochester NY, US
Thaddeus Carlson - Rochester NY, US
Assignee:
University of Rochester - Rochester NY
International Classification:
A61K 49/00
A61K 39/395
G01N 33/68
A61P 37/00
G01N 33/53
US Classification:
424 92, 4241581, 436 86, 435 72
Abstract:
Experimental autoimmune encephalomyelitis (EAE) is a ThI-mediated autoimmune disease of the central nervous system that is widely used as an animal model of multiple sclerosis (MS). Herein it is demonstrated that CXCR2, a chemokine receptor involved in the recruitment of neutrophils, is expressed in tissues with EAE lesions. Blockade or deficiency of CXCR2 reduces the infiltration of neutrophils to sites of inflammation. Thus provided herein are reagents that antagonize or inhibit ELR+CXC chemokines and methods of use of these reagents in preventing and treating organ-specific autoimmune diseases like multiple sclerosis, and methods or treating various inflammatory conditions and diseases.

Compositions And Methods For Inhibiting G-Csfr

US Patent:
2011011, May 19, 2011
Filed:
Oct 18, 2010
Appl. No.:
12/906548
Inventors:
Benjamin M. Segal - Ann Arbor MI, US
Praveen Rao - Ann Arbor MI, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN - Ann Arbor MI
International Classification:
A61K 39/395
C07K 16/24
C07H 21/02
C07H 21/00
A61K 31/713
A61K 31/7088
A61P 29/00
A61P 25/28
A61P 25/00
C07K 16/28
US Classification:
4241341, 5303873, 5303892, 536 245, 4241581, 514 44 A, 5303896, 4241731
Abstract:
The present invention relates to therapeutic targets for multiple sclerosis and other inflammatory and neurological diseases. In particular, the present invention relates to altering G-CSF/G-CSFR signaling in the treatment of such disorders.

Compositions And Methods For Inhibiting Madcam

US Patent:
2011015, Jun 30, 2011
Filed:
Oct 4, 2010
Appl. No.:
12/897532
Inventors:
Benjamin M. Segal - Ann Arbor MI, US
Praveen Rao - Ann Arbor MI, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN - Ann Arbor MI
International Classification:
A61K 39/395
C07K 16/00
A61K 31/713
A61P 29/00
A61P 25/28
US Classification:
4241331, 5303873, 514 44 A
Abstract:
The present invention relates to therapeutic targets for multiple sclerosis and neuroinflammatory diseases and injuries. In particular, the present invention relates to targeting MAdCAM in the treatment of such disorders.

Sleep Apnea Treatment

US Patent:
2019009, Mar 28, 2019
Filed:
Nov 28, 2018
Appl. No.:
16/202730
Inventors:
- Ann Arbor MI, US
Benjamin Segal - Ann Arbor MI, US
Ronald D. Chervin - Ann Arbor MI, US
International Classification:
A61K 38/21
A61K 38/02
A61K 31/194
A61K 38/16
A61K 31/225
A61P 11/00
Abstract:
Provided herein is technology relating to treating sleep apnea and particularly, but not exclusively, to treating sleep apnea with immunotherapeutics and/or anti-inflammatory drugs such as beta-interferons and glatiramer acetate.

Sleep Apnea Treatment

US Patent:
2015013, May 21, 2015
Filed:
Jun 14, 2013
Appl. No.:
14/407786
Inventors:
- Ann Arbor MI, US
Benjamin Segal - Ann Arbor MI, US
Ronald D. Chervin - Ann Arbor MI, US
Assignee:
The Regents of The University of Michigan - Ann Arbor MI
International Classification:
A61K 38/21
A61K 31/225
A61K 38/16
US Classification:
424 7837, 424 856, 514547
Abstract:
Provided herein is technology relating to treating sleep apnea and particularly, but not exclusively, to treating sleep apnea with immunotherapeutics and/or anti-inflammatory drugs such as beta-interferons and glatiramer acetate.

Isbn (Books And Publications)

Returning: The Land Of Israel As Focus In Jewish History

Author:
Benjamin Segal
ISBN #:
0595372074

Possible Relatives

Daniel R Segal  Aaron L Segal  Darren M Segal  Diana L Segal  Donald P Segal  Douglas C Segal  Edward N Segal  Benjamin B Joiner  Benjamin J Stanton  Benjamin O Staples 

NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.